A literature review published in late August 2026 by researchers affiliated with UCLA Health has become one of the most detailed independent assessments yet of the evidence behind six peptides widely sold online as "research chemicals": BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu. The takeaway, as summarized by UCLA Health: marketing claims about these compounds are far ahead of the underlying science.
What the Review Actually Examined
The review, led by UCLA orthopaedic surgeon Dr. Thomas Kremen along with medical student Kushagra Tewari, screened 565 published studies covering the six compounds. According to UCLA Health's summary of the work, more than two-thirds of those studies were conducted exclusively in animals, with results that varied considerably between species and models. The human studies that did exist were generally small and showed at most modest effects, and the reviewers judged that most lacked the controls and rigorous design needed to draw firm conclusions. For the specific claim that drives most marketing to athletes and recreational users, namely musculoskeletal healing and recovery, the review found controlled clinical evidence in humans was essentially nonexistent.
A Safety Flag, Not Just an Efficacy Gap
The review didn't stop at "we don't know if these work." It also raised a specific safety concern: a clinical trial of MK-677 (ibutamoren) was halted after researchers observed an elevated rate of congestive heart failure in one study group. Dr. Kremen also described treating a patient who required hospitalization for cardiac complications following peptide use, a reminder that "research chemical" framing doesn't mean these compounds carry no risk. The review pointed to a manufacturing and supply-chain problem layered on top of the evidence gap: because these are unregulated products, often manufactured overseas and labeled "not for human use," batches can vary in purity and have been found to contain contaminants unrelated to the peptide itself.
Why This Matters for the Regulatory Debate
The timing is notable. Just weeks earlier, in July 2026, an FDA advisory committee voted to recommend several of these same compounds, including BPC-157 and TB-500, for inclusion on the list of substances legally available through pharmacy compounding, a vote covered in more detail elsewhere on this site. That vote was about whether a compound is safe enough to compound under medical supervision and prescription, not whether it has been proven effective for any particular use, and this new review is a reminder of how separate those two questions really are. A compound can clear a safety-focused compounding review while still lacking the controlled human trials needed to establish that it actually does what it is marketed to do.
The Bottom Line
None of the six peptides in this review are FDA-approved for any use, and this new analysis doesn't change that. What it adds is a more precise picture of how far current evidence lags behind the marketing built around these compounds: mostly animal data, occasional small human studies with modest results, and at least one documented serious safety signal. If you're considering any of these products, that gap, not a vendor's product description, is the information worth weighing, and it's worth raising directly with a doctor before starting or continuing use.